Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus
Jodi L. Karnell(Integrated BioTherapeutics (United States)), Antonio Terrelonge(Certis USA (United States)), Jill Hénault, José Luís Marenco de la Fuente, Steven N. Mathews, Vishala Chindalore(Pinnacle Clinical Research), Simone M. Nicholson(AstraZeneca (United States)), Victoria P. Werth(Philadelphia VA Medical Center), William A. Rees(Mayo Clinic), Sławomir Jeka, Theresa Lawrence Ford(Georgia Urology), Anne L. Marano, Gabor G. Illei(National Institutes of Health), Kerry A. Casey(AstraZeneca (United States)), Miguel A. F. Sanjuán(Real Academia Española), Lidia Rudnicka(Medical University of Warsaw), Adam Reich(Rzeszów University of Technology), Katherine A. Vousden(Aimmune Therapeutics (United Kingdom)), Alan Kivitz(Altoona Center for Clinical Research), John N. Ratchford(Johns Hopkins University), Michele Gunsior(Integrated BioTherapeutics (United States)), Yanping Wu(Integrated BioTherapeutics (United States)), Michael A. Smith(Creighton University), Ramesh K. Gupta(Baptist Memorial Hospital), Nanette Mittereder(Integrated BioTherapeutics (United States)), Winn Chatham(University of Alabama at Birmingham), Alla Rudinskaya(Danbury Hospital), Jeffrey M. Riggs(AstraZeneca (Netherlands)), Jörn Drappa(Integrated BioTherapeutics (United States))
Cited by 120
Related Papers
The Majority of MicroRNAs Detectable in Serum and Saliva Is Concentrated in Exosomes
|PLoS ONE|2012|1.1k
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
|Journal of the American Academy of Dermatology|2008|586